Sustained-release delivery of prostacyclin analogue(ONO-1301) enhances lung regeneration after pnuemonectomy in mice

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10255
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Osaka University
• Principal Investigator: Minami Masato 大阪大学, 医学部附属病院, 准教授 (10240847)
• Co-Investigator(Kenkyū-buntansha): 井上 匡美 京都府立医科大学, 医学(系)研究科(研究院), 教授 (10379232) ; 川村 知裕 大阪大学, 医学系研究科, 助教 (30528675) ; 奥村 明之進 大阪大学, 医学系研究科, 教授 (40252647) ; 舟木 壮一郎 大阪大学, 医学系研究科, 講師 (50464251) ; 新谷 康 大阪大学, 医学系研究科, 准教授 (90572983)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺再生 / 慢性閉塞性肺疾患 / プロスタサイクリンアナログ / HGF

Outline of Final Research Achievements

ONO1301 is a synthetic prostacyclin analog characterized by chemically stable structure and enhances hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) secretion. Here, we hypothesized that sustained delivery of ONO1301 may induce therapeutic effects of residual lung compensatory lung growth after left pneumonectomy in mice. In histopathological findings, the enlarged airspace and emphysematous change of residual lung were suppressed in the presence of ONO1301 groups(ONO) as compared to control groups(Con). From the results of hyperpolarized 129Xe MRI, the parameters of gas exchange and Septal-to-alveolar volume ratio (Vs/Va) of ONO were significantly higher than that of Con (p>0.05) . In lung function test, lung compliance (c chord) of ONO were significantly decreased as compared to Con. In conclusion, our results suggest that ONO has an important candidate as a promotive agent in postpneumonectomy compensatory lung regeneration.

Free Research Field

呼吸器外科学